BOSTON, MA – May 27, 2025 – Lumanity, a global strategic services partner is bolstering its strategy consulting leadership with the appointment of Richard Nieman, MD, as Executive Vice President, Medical Strategy. This addition enhances Lumanity’s global team of over 250 consultants across the US, UK, and EU, focused on helping clients unlock the transformative potential of their assets and organizations.
“We are thrilled to welcome Richard to Lumanity,” said Tom Murtagh, Joint Global Practice Lead of Strategy & Insight at Lumanity. “We have been building the premier next generation strategic services partner that is capable of helping our clients make critical decisions throughout the development and commercialization journey of truly innovative therapies that add breakthrough value for all stakeholders. This has become increasingly difficult and risky for clients, given the abundant innovation pipeline, seeking to progress amidst great market uncertainty and increasingly value-focused decision-makers. At Lumanity we continue to work at the intersection of science, clinical practice and economics; and we understand the importance that senior medical advisors play in this equation. We are honored to have a Medical / R&D leader as seasoned as Richard joins us to help deliver on our Lumanity vision.”
Dr. Richard Nieman, a pharmaceutical physician and leader in drug development and medical affairs, joins Lumanity with extensive global experience in leading Medical and Drug Development Organizations. He has held senior medical leadership roles, notably at Bayer, Teva and at Bristol Myers Squibb. At Teva, one of the world’s leading pharmaceutical companies, Richard was Senior Vice President and Head of Medical Affairs and a member of the Specialty Executive Team. His international experience includes significant roles in the US, Europe, the UK, and Asia, notably leading R&D in China and global medical strategy for immunology at BMS. Richard is a trained respiratory physician, an elected Fellow of the Royal College of Physicians (UK) and was previously a Visiting Professor at the School of Public Health, Fudan University, Shanghai, China, one of the preeminent centers in China for Health Policy and Health Economics. Dr. Nieman has a proven track record of building and leading large global teams and shaping impactful medical strategies leading to multiple successful global product launches.
“My background at the intersection of Medical Affairs and Drug Development, coupled with my international experience, provides a unique lens on the challenges and opportunities within the pharmaceutical landscape,” said Dr. Nieman. “I am thrilled to join Lumanity and contribute to their mission of accelerating access to innovative medicines by strategically bridging these critical functions for our partners and thereby continuing to bring medicines to patients in need.”
